# Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

> **NCT07221942** · PHASE2 · RECRUITING · sponsor: **Fox Chase Cancer Center** · enrollment: 97 (estimated)

## Conditions studied

- Metastatic Urothelial Carcinoma
- Unresectable Urothelial Carcinoma
- Advanced Urothelial Carcinoma

## Interventions

- **DRUG:** Enfortumab vedotin
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07221942
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-23
- **Primary completion:** 2028-09-01
- **Final completion:** 2029-09-03
- **Target enrollment:** 97 (ESTIMATED)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221942, "Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07221942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*